Featured Products |
 |
 |
PERNIX THERAPEUTICS INTRODUCES OMECLAMOX-PAK®, FIRST PRODUCT IN GASTROENTEROLOGY PORTFOLIO
Posted on 05/15/2012
Omeclamox-Pak® eradicates Helicobacter pylori bacteria infection in just ten days THE WOODLANDS, Texas, May 15, 2012—Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter [...]
PERNIX THERAPEUTICS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS
Posted on
First Quarter of 2012 Net Revenues Increased Approximately 43% to $14.5 Million from $10.1 Million in the First Quarter of 2011 Launch of Omeclamox-Pak® as a Branded Prescription Treatment for H. pylori Infection and Duodenal Ulcer Disease On Track for the Summer of 2012 Secures Exclusive Rights to the Cough-Related Intellectual Property from its Joint [...]
» Continue Reading PERNIX THERAPEUTICS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS
Pernix Therapeutics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Posted on 05/09/2012
THE WOODLANDS, Texas, May 9, 2012 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced that Cooper Collins, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, 2012 at 11:20 a.m. PDT. The conference will be held [...]
Pernix Therapeutics to Report First Quarter 2012 Financial Results on May 15, 2012
Posted on 05/07/2012
Management to Host a Conference Call on May 15 at 9:00 a.m. EDT THE WOODLANDS, Texas, May 7, 2012 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2012 financial results before the U.S. stock market opens on Tuesday, May 15, 2012 and [...]
» Continue Reading Pernix Therapeutics to Report First Quarter 2012 Financial Results on May 15, 2012
Pernix Therapeutics Completes At-the-Market Equity Offering
Posted on 04/26/2012
THE WOODLANDS, Texas, April 26, 2012 – Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has completed its At-the-Market (ATM) offering with Cantor Fitzgerald & Co. Today, the Company sold approximately 2.7 million shares of common stock under the ATM agreement for total net [...]
» Continue Reading Pernix Therapeutics Completes At-the-Market Equity Offering